ABEONA THERAPEUTICS INC. cotiza a 4.52 USD y tiene una capitalización bursátil de $258M. En los últimos 12 meses ha facturado $26M con un margen de flujo de caja libre del -1448.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develo…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.30 | $-0.37 |
| Estimado | $-0.17 | $-0.24 | $-0.39 | $-0.37 |
| Sorpresa | — | — | +23.1% | +0.0% |
| Métrica | ABEO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 73.7% | 57.0% | +16.6% |
| Operating Margin | -1536.9% | -38.6% | -1498.3% |
| Net Margin | 1223.1% | -33.6% | +1256.6% |
| FCF Margin | -1448.5% | -13.9% | -1434.6% |
| ROE | 44.7% | -40.4% | +85.1% |
| ROA | 32.4% | -32.0% | +64.4% |
| Current Ratio | 6.93 | 2.84 | +4.09 |
| Debt / Equity | 0.13 | 0.28 | -0.15 |